AAAAAA

   
Results: 1-7 |
Results: 7
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
Authors: Anderson, KM Califf, RM Stone, GW Neumann, FJ Montalescot, G Miller, DP Ferguson, JJ Willerson, JT Weisman, HF Topol, EJ
Citation: Km. Anderson et al., Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention, J AM COL C, 37(8), 2001, pp. 2059-2065
Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
Authors: Topol, EJ Ohman, EM Barnathan, E Califf, RM Lee, KL Lincoff, AM Ohman, EM Scherer, J Scott, R Sketch, MH Topol, EJ Weisman, HF Cantor, W Evans, B Harris, J Kirby, J Miller, J Minshall, D Oliverio, RM Stebbins, AL Webb, L Wittlief, J Topol, EJ Lincoff, AM Moliterno, DJ Ivanc, T Barnathan, E Damaraju, L Hadley, K Kukulewicz, L Scherer, J Scott, R Schwarz, R Waller, M Weisman, H Lincoff, AM Bachinsky, WB Bell, C Butler, JF David, SW Gibbs, K Sakhaii, M Hanovich, G Herrmann, H Hillegass, W Kereiakes, DJ Kiernan, J McGrew, FA Miklin, JS Miller, L Sketch, MH Riba, A Schreiber, TL Smalling, RW Talley, JD Worley, S Bates, ER Hearne, S Morris, DC Priest, MF Pelikan, P Seals, AA Smith, JE Bach, RG Laufer, N Phillips, PS McClure, R Navetta, FI Bhoopalam, V Aylward, PE Ardissino, D Betriu, A della Misericordi, OSM Morocutti, G Muller, DWM Grinfeld, L Cagide, A Bode, C Forycki, F Lefkovits, J Steg, G Macaya, C Schultheiss, HP Eberli, F
Citation: Ej. Topol et al., Trial of abciximab with and without low-dose reteplase for acute myocardial infarction, CIRCULATION, 101(24), 2000, pp. 2788-2794
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonistabciximab
Authors: Mascelli, MA Kleiman, NS Marciniak, SJ Damaraju, L Weisman, HF Jordan, RE
Citation: Ma. Mascelli et al., Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonistabciximab, AM HEART J, 139(4), 2000, pp. 696-703
Platelet glycoprotein IIb/IIIa antagonists in ischemic cerebrovascular disease
Authors: Leclerc, JR Mascelli, MA Weisman, HF
Citation: Jr. Leclerc et al., Platelet glycoprotein IIb/IIIa antagonists in ischemic cerebrovascular disease, CORON ART D, 10(8), 1999, pp. 575-579
Current antiplatelet therapy
Authors: Jakubowski, JA Jordan, RE Weisman, HF
Citation: Ja. Jakubowski et al., Current antiplatelet therapy, HANDB EXP P, 132, 1999, pp. 175-208
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab - One-year outcome in the EPILOG trial
Authors: Lincoff, AM Tcheng, JE Califf, RM Kereiakes, DJ Kelly, TA Timmis, GC Kleiman, NS Booth, JE Balog, C Cabot, CF Anderson, KM Weisman, HF Topol, EJ
Citation: Am. Lincoff et al., Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab - One-year outcome in the EPILOG trial, CIRCULATION, 99(15), 1999, pp. 1951-1958
An industry perspective on health economics studies
Authors: Anderson, KM Bala, MV Weisman, HF
Citation: Km. Anderson et al., An industry perspective on health economics studies, AM HEART J, 137(5), 1999, pp. S129-S132
Risultati: 1-7 |